Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study

SIMPLE SUMMARY: Giant cell tumors of bone (GCTB) are a histologically benign, yet often aggressive, skeletal tumor. Surgery is the only potentially curative treatment option, but may be associated with severe morbidity and loss of function. Denosumab, a monoclonal antibody directed to RANK ligand, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmerini, Emanuela, Pazzaglia, Laura, Cevolani, Luca, Pratelli, Loredana, Pierini, Michela, Quattrini, Irene, Carretta, Elisa, Manara, Maria Cristina, Pasello, Michela, Frega, Giorgio, Paioli, Anna, Longhi, Alessandra, Cesari, Marilena, Hakim, Rossella, Ibrahim, Toni, Campanacci, Laura, Staals, Eric Lodewijk, Donati, Davide Maria, Benassi, Maria Serena, Scotlandi, Katia, Ferrari, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220940/
https://www.ncbi.nlm.nih.gov/pubmed/35740530
http://dx.doi.org/10.3390/cancers14122863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220940/
https://www.ncbi.nlm.nih.gov/pubmed/35740530
http://dx.doi.org/10.3390/cancers14122863

Ejemplares similares